ABOVE: University of California, Berkeley
© ISTOCK.COM, LUCENTIUS
The University of California, Berkeley, and its partners in developing CRISPR gene editing will receive the patent at the heart of an intellectual property dispute between the Berkeley team and the Broad Institute and its CRISPR collaborators. On Friday (February 8), the US Patent and Trademark Office issued a “notice of allowance” for the UCB patent, indicating that it will be awarded in the coming weeks.
According to a statement from Berkeley, the molecular technology covered by the patent includes single guide RNAs combined with the Cas9 nuclease to cut DNA in any cellular or in vitro context.
“We are pleased the patent application is now allowed and that the issued patent will encompass the use of CRISPR-Cas9 technology in any cellular or non-cellular environment,” Eldora Ellison, the lead patent strategist on CRISPR matters for the University of California and a director ...
